Key result
Higher adiponectin is linked to ~56% lower pancreatic cancer risk in never-smokers only.
Why the study?
Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased adiponectin levels, but the association of pre-diagnostic adiponectin with pancreatic cancer risk is unclear.
Are higher pre-diagnostic circulating adiponectin levels associated with a reduced risk of pancreatic cancer?
Population
452 pancreatic cancer cases and 452 individually matched controls from EPIC cohort
Comparison
Higher vs lower pre-diagnostic circulating adiponectin levels
Design
Case-control study nested within prospective cohort
Authors
Loading...
Adiponectin levels should not inform pancreatic cancer risk assessment; leaves open smoking-stratified associations for prospective confirmation.
Case-Control (n=904)
Yes
Are higher pre-diagnostic circulating adiponectin levels associated with a reduced risk of pancreatic cancer?
Odds Ratio: 0.44 (95% CI 0.23–0.82)
Higher circulating adiponectin levels may be associated with a reduced risk of pancreatic cancer specifically among never smokers, though there is no overall association.
Grote et al. (2011) conducted a case-control in Pancreatic cancer (n=904). Circulating adiponectin levels vs. Lowest quartile of adiponectin levels was evaluated on Pancreatic cancer risk (OR 0.44, 95% CI 0.23-0.82). Higher circulating adiponectin levels were associated with a reduced risk of pancreatic cancer among never smokers (OR 0.44; 95% CI 0.23-0.82), though no significant association was found overall.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: